HUTCHMED (China) annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
HUTCHMED (China) Revenue Growth & History (HCM)
HUTCHMED (China) reported $548.5M in revenue for fiscal 2025, a decrease of 12.96% from the previous fiscal year.
View full HUTCHMED (China) company overviewHUTCHMED (China) annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $548.5M | −$81.7M | −12.96% |
| 2024 | 2024-12-31 | $630.2M | −$207.8M | −24.80% |
| 2023 | 2023-12-31 | $838.0M | $411.6M | +96.52% |
| 2022 | 2022-12-31 | $426.4M | $70.3M | +19.73% |
| 2021 | 2021-12-31 | $356.1M | $128.2M | +56.21% |
| 2020 | 2020-12-31 | $228.0M | $23.1M | +11.27% |
| 2019 | 2019-12-31 | $204.9M | −$9.2M | −4.31% |
| 2018 | 2018-12-31 | $214.1M | −$27.1M | −11.23% |
| 2017 | 2017-12-31 | $241.2M | $25.1M | +11.63% |
| 2016 | 2016-12-31 | $216.1M | $37.9M | +21.25% |
| 2015 | 2015-12-31 | $178.2M | $90.9M | +104.06% |
| 2014 | 2014-12-31 | $87.3M | — | — |
HUTCHMED (China) quarterly revenue
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q4 2019 | 2019-12-31 | $53.3M | $236,000 | +0.44% |
| Q3 2019 | 2019-09-30 | $49.3M | −$9.5M | −16.09% |
| Q2 2019 | 2019-06-30 | $50.0M | $177,000 | +0.36% |
| Q1 2019 | 2019-03-31 | $52.2M | −$169,000 | −0.32% |
| Q4 2018 | 2018-12-31 | $53.1M | — | — |
| Q3 2018 | 2018-09-30 | $58.8M | — | — |
| Q2 2018 | 2018-06-30 | $49.9M | — | — |
| Q1 2018 | 2018-03-31 | $52.3M | — | — |
HUTCHMED (China) revenue growth trends
Over the last five reported fiscal years, revenue grew from $228.0M to $548.5M, a compound annual growth rate of 19.20%. HUTCHMED (China)'s latest reported quarter, Q4 2019, generated $53.3M in revenue, an increase of 0.44% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review HUTCHMED (China) source filings ↗Community posts
AstraZeneca files US application for lung-cancer combination developed with HUTCHMED
HUTCHMED ($HCM) said AstraZeneca ($AZN) submitted a US new drug application for savolitinib, marketed as ORPATHYS in other jurisdictions, combined with TAGRISSO. The proposed use is MET-driven, EGFR-mutated advanced non-small-cell lung canc ...
